Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of RMC-4630 in combination with an emerging asset from AstraZeneca's preclinical efforts targeting KRASG12C

Next Previous
X
Search
Trial Profile

A clinical study of RMC-4630 in combination with an emerging asset from AstraZeneca's preclinical efforts targeting KRASG12C

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vociprotafib (Primary)
  • Indications Cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 30 Oct 2020 New trial record
    • 24 Oct 2020 According to a REVOLUTION Medicines media release, it has signed an agreement with AstraZeneca to enter a clinical collaboration to study RMC-4630 in combination with an emerging asset from AstraZenecas preclinical efforts targeting KRASG12C. Under the agreement, AstraZeneca will sponsor and conduct this combination study and Revolution Medicines will provide clinical supply of RMC-4630.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top